Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab for macular edema secondary to branch retinal vein occlusion – early macular microcirculation changes (China, prospective observational)
ChiCTR2500106303Phase 4Not yet recruiting
- Sponsor
- The 2nd Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of faricimab in branch retinal vein occlusion (BRVO), sponsored by The 2nd Affiliated Hospital of Chongqing Medical University. Primary endpoints: Visual acuity, Multifocal electroretinogram (mfERG) and 9 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
faricimab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on ChiCTR2500106303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106303.